Allele Biotech is the pioneering provider of cGMP-grade iPSCs (Induced Pluripotent Stem Cells) for cell therapy. As the first dedicated provider, Allele offers a comprehensive range of products and services to accelerate life-saving immuno-oncology and regenerative medicine cell therapies. With over a decade of experience, Allele has mastered personalized iPSC approaches, serving clients ranging from start-ups to biopharma companies.

Allele produces the highest quality commercial-ready iPSCs, ensuring consistency, scalability, and ethical standards. These iPSC lines can be easily scaled-up or frozen down, saving valuable time and resources. By reducing your development time and optimizing cost-effectiveness per dose, Allele's off-the-shelf iPSC lines provide a clean slate for cell therapy development.

What sets Allele apart is their robust technology, using a proprietary patented mRNA system to generate footprint-free, feeder-free, and xeno-free iPSCs. With no risk of genomic integration and no vector cleanup phase, Allele's iPSCs meet strict regulatory standards, seamlessly transitioning from scientific development to commercial deployment. Discover the potential of iPSCs in cell therapy with Allele Biotech.

Download their informative buyer's guide on donor cell sourcing, or contact them to find the best fit for your specific needs. Allele Biotech is committed to unlocking the future of regenerative medicine and enhancing patient outcomes